Skip to menu Skip to content Skip to footer

Novel polymeric microparticles for slow-release intrathecal delivery of analgesics (2010-2013)

Abstract

Unrelieved pain is a large area of unmet medical need, adversely affecting the lives of millions of people worldwide. This project seeks to utilise innovative, green, polymer chemistry to develop bioerodable polymer particles to deliver the novel analgesic agent, Xen2174, into the spinal fluid in close proximity to its target receptors. The overall goal is to use this approach to produce prolonged periods of analgesia in the 10-30% of patients who do not obtain benefit from existing analgesic treatments delivered by less invasive routes. This bioerodable polymer technology has potential broad application to a wide range of drug treatments.

Experts

Emeritus Professor Maree Smith

Emeritus Professor
School of Biomedical Sciences
Faculty of Medicine
Maree Smith
Maree Smith

Professor Andrew Whittaker

Professorial Research Fellow and Se
Australian Institute for Bioengineering and Nanotechnology
Affiliate of Australian Research Co
ARC Centre of Excellence-Green Electrochemical Transformation of Carbon Dioxide
Faculty of Engineering, Architecture and Information Technology
Affiliate Professor
School of Chemistry and Molecular Biosciences
Faculty of Science
Andrew Whittaker
Andrew Whittaker

Professor Kristofer Thurecht

Senior Group Leader and Deputy Dire
Centre for Advanced Imaging
Australian Institute for Bioengineering and Nanotechnology
Affiliate PRF & Group Leader
Australian Institute for Bioengineering and Nanotechnology
Kristofer Thurecht